Timber Pharmaceuticals Inc. [AMEX: TMBR] price plunged by -7.25 percent to reach at $0.0. The company report on October 3, 2022 that Timber Pharmaceuticals Announces $1.3 Million Registered Direct Offering.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
In a concurrent private placement, the Company has also agreed to issue to the investors: (i) Series 2 warrants (the “Series 2 Warrants”) to purchase up to an aggregate of 13,000,000 shares of Common Stock, and (ii) 13,000 shares of Series B Mirroring Preferred Stock (the “Series B Preferred Stock”). Each share of Series B Preferred Stock will have a stated value of $0.001 per share. The Series 2 Warrants will become exercisable six (6) months following the date of issuance at an exercise price of $0.12 per share and will expire two and one-half years following the initial exercise date.
A sum of 6291861 shares traded at recent session while its average daily volume was at 14.02M shares. Timber Pharmaceuticals Inc. shares reached a high of $0.09 and dropped to a low of $0.07 until finishing in the latest session at $0.08.
The one-year TMBR stock forecast points to a potential upside of 94.67. The average equity rating for TMBR stock is currently 2.00, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on Timber Pharmaceuticals Inc. [TMBR]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for TMBR shares is $1.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on TMBR stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
The Average True Range (ATR) for Timber Pharmaceuticals Inc. is set at 0.01, with the Price to Sales ratio for TMBR stock in the period of the last 12 months amounting to 22.74. The Price to Book ratio for the last quarter was 3.77, with the Price to Cash per share for the same quarter was set at 0.06.
TMBR Stock Performance Analysis:
Timber Pharmaceuticals Inc. [TMBR] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -9.15. With this latest performance, TMBR shares dropped by -35.47% in over the last four-week period, additionally sinking by -75.43% over the last 6 months – not to mention a drop of -89.44% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for TMBR stock in for the last two-week period is set at 30.02, with the RSI for the last a single of trading hit 24.84, and the three-weeks RSI is set at 32.39 for Timber Pharmaceuticals Inc. [TMBR]. The present Moving Average for the last 50 days of trading for this stock 0.1096, while it was recorded at 0.0821 for the last single week of trading, and 0.2540 for the last 200 days.
Insight into Timber Pharmaceuticals Inc. Fundamentals:
Return on Total Capital for TMBR is now -762.38, given the latest momentum, and Return on Invested Capital for the company is -1,126.40. Return on Equity for this stock declined to -2,020.23, with Return on Assets sitting at -334.96. Additionally, TMBR Total Debt to Total Capital is recorded at 127.27, with Total Debt to Total Assets ending up at 74.27.
Reflecting on the efficiency of the workforce at the company, Timber Pharmaceuticals Inc. [TMBR] managed to generate an average of -$3,229,000 per employee.Timber Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.40 and a Current Ratio set at 1.40.
Timber Pharmaceuticals Inc. [TMBR] Insider Position Details
There are presently around $0 million, or 1.30% of TMBR stock, in the hands of institutional investors. The top three institutional holders of TMBR stocks are: VANGUARD GROUP INC with ownership of 1,172,767, which is approximately 0% of the company’s market cap and around 0.30% of the total institutional ownership; GEODE CAPITAL MANAGEMENT, LLC, holding 239,329 shares of the stock with an approximate value of $18000.0 in TMBR stocks shares; and NORTHERN TRUST CORP, currently with $9000.0 in TMBR stock with ownership of nearly 102.349% of the company’s market capitalization.
Positions in Timber Pharmaceuticals Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 10 institutional holders increased their position in Timber Pharmaceuticals Inc. [AMEX:TMBR] by around 252,978 shares. Additionally, 4 investors decreased positions by around 1,067,280 shares, while 3 investors held positions by with 573,280 shares. The mentioned changes placed institutional holdings at 1,893,538 shares, according to the latest SEC report filing. TMBR stock had 3 new institutional investments in for a total of 10,978 shares, while 2 institutional investors sold positions of 92,962 shares during the same period.